Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04177498 · ClinicalTrials.gov registry record · Early Phase 1
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
A Early Phase 1 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT04177498: Completed Early Phase 1 study, sponsored by Thomas Jefferson University.
NCT04177498 is a Early Phase 1 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04177498, a Early Phase 1 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot trial studies how rigsertib sodium works in treating patients with Recessive Dystrophic Epidermolysis bullosa (RDEB) with locally advanced Squamous Cell Carcinoma (SCC). Rigosertib may selectively target Epidermolysis bullosa (EB) cancer cells while leaving normal EB cells unaffected.
Primary Outcome
Defined as the proportion of patients who achieve either a complete response (CR) or partial response (PR)
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Rigosertib Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-08-24 |
| Est. Completion | 2025-05-05 |
| Phase | Early Phase 1 |
What the finished NCT04177498 record still lists
NCT04177498 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04177498 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04177498 about?
NCT04177498 is a clinical study titled "Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC". This pilot trial studies how rigsertib sodium works in treating patients with Recessive Dystrophic Epidermolysis bullosa (RDEB) with locally advanced Squamous Cell Carcinoma (SCC). Rigosertib may selectively target Epidermolysis bullosa (EB) cancer cells while leaving normal EB cells unaffected.
What is the current status of trial NCT04177498?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2021-08-24. Estimated completion is 2025-05-05.
What interventions are being tested in trial NCT04177498?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Rigosertib Sodium (DRUG).
Who is sponsoring clinical trial NCT04177498?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04177498's enrollment target sits among peer trials
3 1949th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI